Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.45 |
| ▸ | AGXT | P21549 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682011 | 0.72 | GSK3B (0.36) | GSK3B | |
| SCHEMBL11066703 | 0.71 | IDO1 (0.41) | IDO1AGXTCYP3A4 | |
| SCHEMBL1041647 | 0.70 | — | — | |
| SCHEMBL9030193 | 0.70 | TAAR1 (0.41) | GSK3B | |
| SCHEMBL12299527 | 0.70 | IDO1 (0.39) | IDO1AGXTCYP3A4 | |
| SCHEMBL843790 | 0.69 | — | — | |
| SCHEMBL25306131 | 0.68 | GSK3B (0.35) | IDO1GSK3B | |
| SCHEMBL11068073 | 0.67 | — | — | |
| SCHEMBL25307831 | 0.65 | GSK3B (0.46) | GSK3B | |
| SCHEMBL25299694 | 0.65 | MAOA (0.34) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-8017618-B2 | Administering antifolate anticancer agent and methoxyamine to enhance or increase the effect of the antifolate anticancer agent | TRACON PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-4432786-A | Thienylmethoxyiminoalkyl cyclohexanedione herbicides | CHEVRON RESEARCH COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | IDO1 2814/4885AGXT 779/4885CYP3A4 2579/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | IDO1 4025/4885AGXT 2638/4885CYP3A4 4711/4885 |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | FEN1, UNG, FOLR1 | IDO1 3342/4885AGXT 550/4885CYP3A4 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.